News

November 11, 2020November 11, 2020

Post-surgery Opdivo Found to Reduce Risk of Recurrence in High-risk Bladder Cancer

News

Treatment with Opdivo (nivolumab) after surgery significantly reduces the risk of disease recurrence or death in people with high-risk, muscle-invasive urothelial cancer — a form of bladder cancer — an ... Read more

November 9, 2020November 9, 2020

Opdivo-Yervoy-Chemo Combo Approved in EU for Advanced NSCLC

News

The European Commission has approved a combination of Opdivo (nivolumab) and Yervoy (ipilimumab) plus two cycles of platinum-based chemotherapy as a first-line treatment for people with advanced non-small cell lung cancer (NSCLC) ... Read more

November 6, 2020November 6, 2020

Tecentriq-Avastin Combo Approved in Europe for Advanced or Inoperable Liver Cancer

News

The European Commission has approved the combination of Tecentriq (atezolizumab) and Avastin (bevacizumab) as a first-line treatment for adults with advanced or inoperable hepatocellular carcinoma (HCC), the most common form ... Read more

November 2, 2020November 2, 2020

Libtayo Given FDA Priority Review for Advanced NSCLC With High PD-L1 Levels

News

The U.S. Food and Drug Administration (FDA) has granted priority review to an application seeking the approval of Libtayo (cemiplimab) as a first-line therapy for advanced non-small cell lung cancer (NSCLC) and high PD-L1 levels, according ... Read more

October 30, 2020November 2, 2020

Nearly Half of Imfinzi-treated NSCLC Patients Alive After 4 Years, PACIFIC Update Shows

News

Imfinzi (durvalumab) continues to demonstrate a sustained survival benefit in patients with inoperable, locally advanced non-small cell lung cancer (NSCLC) who had not progressed after platinum-based chemotherapy and radiation therapy, a ... Read more

October 28, 2020October 28, 2020

Opdivo Combo Found to Extend Survival in Advanced Stomach, Esophageal Cancers

News

Adding Opdivo (nivolumab) to standard first-line chemotherapy significantly extends overall survival and delays disease progression or death in adults with inoperable advanced HER2-negative stomach cancer, esophageal adenocarcinoma, or gastroesophageal junction (GEJ) cancer, ... Read more

October 26, 2020October 27, 2020

Opdivo-Cabometyx Granted FDA Priority Review for Newly Diagnosed Advanced Kidney Cancer

News

The U.S. Food and Drug Administration (FDA) has agreed to review applications requesting the approval of Opdivo (nivolumab) in combination with Cabometyx (cabozantinib) for people with advanced renal cell cancer, the most common type of ... Read more

October 23, 2020October 31, 2020

Cancer Vaccine UV1 Plus Keytruda Shows Safety, Early Efficacy in Advanced Melanoma Trial

News

Adding UV1, Ultimovacs’ experimental cancer vaccine, to Keytruda (pembrolizumab) is safe and shows initial signs of effectiveness in adults with previously untreated metastatic melanoma, according to top-line data from a Phase 1 ... Read more

October 21, 2020October 21, 2020

Committee Recommends EU Approval of Opdivo to Treat Advanced Esophageal Cancer

News

A committee of the European Medicines Agency has recommended the approval of Opdivo (nivolumab) for the treatment of people with advanced, inoperable, recurrent, or metastatic esophageal squamous cell carcinoma (ESCC) who ... Read more

October 19, 2020October 19, 2020

Tecartus Recommended for EU Approval as CAR T-cell Therapy for Mantle Cell Lymphoma

News

A committee of the European Medicines Agency (EMA) has recommended the conditional approval of Tecartus (brexucabtagene autoleucel) for the treatment of adults with relapsed or refractory mantle cell lymphoma (MCL). The recommendation ... Read more